转分化作为去势抵抗性前列腺癌小鼠模型治疗耐药机制
研究利用Trp53和Pten联合失活基因工程小鼠模型(NPp53),发现其对阿比特龙无应答并加速进展为神经内分泌分化的去势抵抗性前列腺癌(CRPC-NE)。跨物种计算分析识别出与人类CRPC-NE保守的不良反应主调控因子SOX11,谱系追踪体内实验提供转分化证据。
要点
- NPp53小鼠对阿比特龙无应答,加速进展为神经内分泌分化的CRPC-NE。
- 跨物种分析识别出SOX11等与人类CRPC-NE保守的主调控因子。
- 体内谱系追踪证明局灶和明显神经内分泌区域源自管腔腺癌细胞转分化。
核心结论
- TP53和PTEN失活在阿比特龙耐药及腺癌向CRPC-NE转分化进展中起主要作用。
研究设计与样本
- 研究采用Trp53和Pten联合失活的基因工程小鼠模型(NPp53),并结合跨物种计算分析和体内谱系追踪。
主要发现
- NPp53小鼠对阿比特龙无应答,并加速进展为类似人类治疗相关CRPC-NE的肿瘤。
- 跨物种计算分析识别出与人类CRPC-NE保守的不良反应主调控因子,包括促进NPp53肿瘤来源细胞神经内分泌分化的神经分化因子SOX11。
- 阿比特龙治疗的NPp53前列腺肿瘤包含局灶和/或明显神经内分泌分化区域,以增殖潜能相区分。
- 体内谱系追踪提供明确且定量的证据,表明局灶和明显神经内分泌区域源自管腔腺癌细胞的转分化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current treatments for castration-resistant prostate cancer (CRPC) that target androgen receptor (AR) signaling improve patient survival, yet ultimately fail. Here, we provide novel insights into treatment response for the antiandrogen abiraterone by analyses of a genetically engineered mouse (GEM) model with combined inactivation of Trp53 and Pten, which are frequently comutated in human CRPC. These NPp53 mice fail to respond to abiraterone and display accelerated progression to tumors resembling treatment-related CRPC with neuroendocrine differentiation (CRPC-NE) in humans. Cross-species computational analyses identify master regulators of adverse response that are conserved with human CRPC-NE, including the neural differentiation factor SOX11, which promotes neuroendocrine differentiation in cells derived from NPp53 tumors. Furthermore, abiraterone-treated NPp53 prostate tumors contain regions of focal and/or overt neuroendocrine differentiation, distinguished by their proliferative potential. Notably, lineage tracing in vivo provides definitive and quantitative evidence that focal and overt neuroendocrine regions arise by transdifferentiation of luminal adenocarcinoma cells. These findings underscore principal roles for TP53 and PTEN inactivation in abiraterone resistance and progression from adenocarcinoma to CRPC-NE by transdifferentiation.Significance: Understanding adverse treatment response and identifying patients likely to fail treatment represent fundamental clinical challenges. By integrating analyses of GEM models and human clinical data, we provide direct genetic evidence for transdifferentiation as a mechanism of drug resistance as well as for stratifying patients for treatment with antiandrogens. Cancer Discov; 7(7); 736-49. ©2017 AACR.See related commentary by Sinha and Nelson, p. 673This article is highlighted in the In This Issue feature, p. 653.
引用
- Zou M, Toivanen R, Mitrofanova A, et al. Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer. Cancer Discov. 2017. PMID: 28411207. doi:10.1158/2159-8290.CD-16-1174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。